YB
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Myeloproliferative neoplasms in young patients: clinical features and specific management | 2024 | 84 | 5 | ||||
Low plasma levels of hyaluronic acid might rule out sinusoidal obstruction syndrome after hematopoietic stem cell transplantation | Disease markers | 2023 | 16 | 5 | |||
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs | Blood advances | 2022 | 27 | 12 | |||
Defibrotide Shows Efficacy in the Prevention of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation : A Retrospective Study | Transplantation and cellular therapy | 2022 | 75 | 35 | |||
The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft | Bone marrow transplantation | 2021 | 250 | 0 | |||
A Unique Case of Acquired Hemophilia A Presenting with Transient Ischemic Attack | Acta Haematologica | 2020 | 283 | 208 | |||
COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency | European Journal of Haematology | 2020 | 257 | 114 | |||
Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts | Biology of Blood and Marrow Transplantation | 2020 | 252 | 166 | |||
Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation | Leukemia and Lymphoma | 2018 | 476 | 2 | |||
Validation de l'index de risque lié à la pathologie chez les patients ayant bénéficié d'une allogreffe de cellules souches hématopoïétiques partiellement déplétée en lymphocytes T in vitro | 2018 | 551 | 6 | ||||
Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome | Bone Marrow Transplantation | 2018 | 382 | 0 | |||
FLT3-ITD mutations do not impact the outcome of patients allografted with partial T-cell depleted grafts for AML with normal cytogenetics in first complete remission | Hematological oncology | 2017 | 505 | 3 | |||
Thromboses veineuses splanchniques | Revue médicale suisse | 2017 | 379 | 113 | |||
Protein modelling to understand FGB mutations leading to congenital hypofibrinogenaemia | Haemophilia | 2017 | 477 | 4 | |||
Pegylated interferon alpha-2a for essential thrombocythaemia during pregnancy, outcome and safety: a case series | Haematologica | 2016 | 357 | 0 | |||
Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera? | Future oncology | 2016 | 491 | 3 | |||
Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation | Leukemia & lymphoma | 2016 | 1 163 | 1 | |||
Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index | Bone marrow transplantation | 2016 | 584 | 2 | |||
Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants | Bone marrow transplantation | 2016 | 612 | 4 | |||
Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis | British journal of haematology | 2016 | 451 | 0 | |||
Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study | Neurology® neuroimmunology & neuroinflammation | 2015 | 440 | 288 | |||
Suspicion of heparin-induced thrombocytopenia in internal medicine: How appropriate is the ordering of anti-PF4/heparin antibody testing? | Platelets | 2015 | 626 | 3 | |||
Pacritinib: a new agent for the management of myelofibrosis? | Expert opinion on pharmacotherapy | 2015 | 450 | 2 | |||
Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion | Biology of blood and marrow transplantation | 2014 | 525 | 1 | |||
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation | International journal of hematology | 2014 | 474 | 0 | |||
Surveillance biologique des héparines et du fondaparinux | Revue médicale suisse | 2011 | 543 | 4 | |||
A body-packer with a cocaine bag stuck in the stomach | World journal of radiology | 2011 | 798 | 392 |